

## Inappropriate sinus tachycardia-induced cardiomyopathy during pregnancy and successful treatment with ivabradine

Saim Sağ, Hakan Çoşkun, İbrahim Baran, Sümeyye Güllülü, Ali Aydınlar  
Department of Cardiology, Faculty of Medicine, Uludağ University,  
Bursa-Turkey

### Introduction

Inappropriate sinus tachycardia (IST) during pregnancy may be asymptomatic until maternal heart failure (HF) develops (1). There is no information on the safety of the use of ivabradine in pregnant patients.

### Case Report

A 32-year-old patient, in the 17<sup>th</sup> week of her first pregnancy, was admitted to the local hospital with complaints of palpitations and shortness of breath, which progressed over a month. The patient had no prior history of any cardiac disease. At the time of admission, the electrocardiogram (ECG) of the patient revealed that she had supraventricular tachycardia. When the patient did not respond to adenosine and electrical cardioversion, she was transferred to our hospital. ECG revealed IST with a heart rate (HR) of 152 bpm (Fig. 1a). She was continuously monitored, and intravenous esmolol infusion and oral metoprolol were started. Due to the high HR, verapamil (240 mg/day) and digoxin (0.25 mg/day) were added, and HR decreased to 120 bpm (Fig. 1b). Echocardiography showed normal left ventricular (LV) dimensions, LV ejection fraction (LVEF) at 45%, and mild mitral regurgitation (MR). On the 7<sup>th</sup> day of hospitalization, LVEF decreased to 40%, followed by a decrease to 30% at the end of the 2<sup>nd</sup> week. The patient developed severe MR. Furosemide was added to the treatment, but the patient did not experience clinical relief. After receiving the patient's consent, we began ivabradine treatment (2x5 mg), and the patient's HR dropped to 90 bpm (Fig. 1c) and remained normal until discharge (Fig. 1d). Prior to ivabradine treatment, fetal echocardiography showed the fetal HR to be 156 bpm (Fig. 2a). After the 1<sup>st</sup> day of ivabradine treatment, the fetal HR was 150 bpm (Fig. 2b), and on the 7<sup>th</sup> day, it was 148 bpm (Fig. 2c). However, it did not decline further until delivery. When the patient's HR returned to normal, LVEF improved each day and reached 50% and MR reduced. Maternal tachycardia and fetal bradycardia were not detected during the monthly follow-ups. A healthy baby boy was delivered. The baby was only fed with breast milk, and on 15<sup>th</sup> day, ECG showed sinus rhythm with an HR of 180 bpm (Fig. 2d).

### Discussion

Persistent IST is a rare atrial tachycardia characterized by an exaggerated increase in HR (usually  $\geq 100$  bpm at rest)




Figure 1. The electrocardiogram (ECG) taken at the time of admission showed that the patient had sinus tachycardia with a heart rate of 152 bpm (a). Following a maximum treatment regimen (200 mg/day of metoprolol, 0.25 mg/day of digoxin, and 240 mg/day of verapamil), the ECG showed sinus tachycardia with the heart rate of 120 bpm (b). After ivabradine treatment, the ECG showed sinus rhythm with the heart rate reduced to 90 bpm (c), and the ECG at discharge showed sinus rhythm within the normal range (d)



Figure 2. Prior to starting treatment with ivabradine, fetal echocardiography showed a heart rate of 156 bpm (a). On the 1<sup>st</sup> day of ivabradine treatment, the fetal ECG showed that the fetal heart rate was 150 bpm (b). On the 1<sup>st</sup> week of ivabradine treatment, the fetal heart rate reduced to 148 bpm (c). After delivery, the mother continued her ivabradine treatment, and the ECG of the baby, who was fed only breast milk, showed sinus rhythm with a heart rate of 180 bpm (d)

with “normal” P waves on ECG. P-wave morphology is usually similar or identical to sinus rhythm. In general, IST is a diagnosis made by exclusion. The treatment for IST has been limited to calcium channel blockers, beta-blockers, antiarrhythmic drugs, and sometimes, radiofrequency ablation. Although metoprolol, verapamil, and digoxin were used in maximum doses in our patient, the control of HR was not achieved and LVEF deteriorated each day, which led to the development of symptomatic HF.

The most popular choice for patients with drug-refractory IST is sinus node modification using radiofrequency ablation (2, 3). However, our patient did not agree to undergo the procedure because of risks such as ionizing radiation, phrenic nerve injury, requirement for permanent pacing, and pericarditis.

A specific HR reducing agent (through the inhibition of pacemaker If current), ivabradine has been documented to be effective for treating angina pectoris and HF (4, 5). The benefit of ivabradine in patients with drug-refractory IST has been described (3–6). There is no information regarding the safety of ivabradine use during pregnancy. In the literature, there is only one study by Babic et al. (7) that demonstrates the administration of ivabradine to a first-trimester pregnant patient presenting with myocardial infarction.

The success of ivabradine treatment for IST-associated cardiomyopathy has been reported in 2 patients in the literature (8, 9). With the improvement of tachycardia, the patients’ clinical symptoms and LVEF also improved, and reduction in MR was observed.

In rats, ivabradine has been shown to pass to the breast milk, but its effect is unknown (10). In our patient, the baby was only fed breast milk and neither bradycardia nor cardiac dysfunction was observed. Therefore, we concluded that ivabradine did not pass to breast milk in amounts that affect the baby’s HR.

## Conclusion

We have shown that ivabradine treatment improved tachycardia and HF in a pregnant patient with IST-induced cardiomyopathy. In addition, no maternal and fetal side effects were observed. However, further studies are still needed to evaluate the use of ivabradine treatment during pregnancy and breastfeeding.

## References

1. Szumowski L, Szuffladowicz E, Orczykowski M, Bodalski R, Derejko P, Przybylski A, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. *J Cardiovasc Electrophysiol* 2010; 21: 877-82. [\[CrossRef\]](#)
2. Gianni C, Di Biase L, Mohanty S, Gökoğlan Y, Güneş MF, Horton R, et al. Catheter ablation of inappropriate sinus tachycardia. *J Interv Card Electrophysiol* 2015 Aug 27. Epub ahead of print.
3. Salazar Adum JP, Arora R. Treatment for inappropriate sinus tachycardia. *Am J Ther* 2015 Sep 16. Epub ahead of print.
4. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. *Lancet* 2008; 372 :807-16. [\[CrossRef\]](#)
5. Mason PK, Di Marco JP. New pharmacological agents for arrhythmias. *Circ Arrhythm Electrophysiol* 2009; 2: 588-97. [\[CrossRef\]](#)
6. Rakovec P. Treatment of inappropriate sinus tachycardia with ivabradine. *Wien Klin Wochenschr* 2009; 121: 716-8. [\[CrossRef\]](#)
7. Babic Z, Gabric ID, Pintaric H. Successful primary percutaneous coronary intervention in the first trimester of pregnancy. *Catheter Cardiovasc Interv* 2011; 77: 522-5. [\[CrossRef\]](#)
8. Winum PF, Cayla G, Rubini M, Beck L, Messner-Pellenc P. A case of cardiomyopathy induced by inappropriate sinus tachycardia and cured by ivabradine. *Pacing Clin Electrophysiol* 2009; 32: 942-4. [\[CrossRef\]](#)
9. Bohora S, Lokhandwala Y, Parekh P, Vasavda A. Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine. *J Cardiovasc Electrophysiol* 2011; 22: 340-2. [\[CrossRef\]](#)
10. Kockova R, Svatonkova J, Novotny J, Hejnova L, Ostadal B, Sedmera D. Heart rate changes mediate the embryotoxic effect of antiarrhythmic drugs in the chick embryo. *Am J Physiol Heart Circ Physiol* 2013; 304: 895-902. [\[CrossRef\]](#)

**Address for Correspondence:** Dr. Saim Sağ  
Uludağ Üniversitesi Tıp Fakültesi Kardiyoloji Anabilim Dalı  
16059, Bursa- Türkiye  
Phone: +90 224 295 16 40 Fax: +90 224 295 16 28  
E-mail: saimsag@gmail.com

©Copyright 2016 by Turkish Society of Cardiology - Available online at [www.anatoljcardiol.com](http://www.anatoljcardiol.com)  
DOI:10.14744/AnatolJCardiol.2016.6813



## A rare side effect seen due to the use of apixaban: Palmoplantar psoriasiform drug eruption

**Vusal Veliyev, İbrahim Özmen<sup>1</sup>, Salim Yaşar, Erol Gürsoy, Mustafa Köklü, Murat Çelik**  
**Department of Cardiology, Gülhane Military Medical Academy, School of Medicine, Ankara-Turkey**  
**<sup>1</sup>Service of Dermatology, Çorlu Military Hospital, Tekirdağ-Turkey**

### Introduction

Psoriasiform drug eruptions are very rare and generally characterized as erythematous, thick, dry, squamous, and demarcated plaques, resembling those of idiopathic psoriasis (1). Drugs may result in the exacerbation of pre-existing psoriasis or initiation of de novo psoriatic lesions (2). Apixaban, a reversible direct inhibitor factor Xa, is a novel anticoagulant, and its side effects mainly include clinically relevant major and non-major bleeding. Although <1% of patients receiving apixaban develop hypersensitivity reactions (including skin rash and anaphylactic reactions such as allergic edema) (3), there is no published case report demonstrating a psoriasiform drug eruption associated with apixaban. We report a psoriasiform drug eruption induced by apixaban.